VIVUS Showing High Volatility Ahead of FDA - VVUS, RITT, URBN, GMXR, ANTH

VIVUS, Inc. (NASDAQ:VVUS) stock declined 0.82% to $28.47 after the company is waiting for the US Food and Drug Administration to soon approve the company’s diet drug Qnexa. The FDA is scheduled to issue a decision by the end of Tuesday.

RiT Technologies Ltd. (NASDAQ:RITT) shares soared 28.42% to $3.75 after the company announced that its SMART Xlight end-to-end fiber optic cabling solution has been certified by an independent laboratory to exceed 10 Gb/s and 100Gb/s performance requirements as specified in the ANSI/TIA-568-C standard. The independent testing was performed by Intertek, across multiple channel configurations that included RiT SMART Xlight end-to-end 10G configuration, RiT SMART Xlight end-to-end 100G configuration, LC multi-mode cords, LC-MPO cassettes, MPO-MPO pre-terminated cables, LC-LC cassettes and MPO cords, in both intelligent and non-intelligent architectures.

Urban Outfitters, Inc. (NASDAQ:URBN) shares climbed3.71% to $30.58 in the early hour. The 52 week trading range for the company is $21.47 - $33.90. The shares of the company gained 21% in the last six months. Investors are bidding up shares of Urban Outfitters today following the addition of the stock to Morgan Stanley's "Best Ideas" list earlier. The firm believes that the recently-range bound stock is ready to break out as the company has shaken-up management and "decisively" cleared excess product. Earnings could double over the next three years, according to Morgan Stanley.

GMX Resources Inc. (NYSE:GMXR) shares gained 1.66% to $0.925 in the morning hour after the company announced that the Company has engaged Global Hunter Securities as financial advisor in connection with a proposed sale of a portion of the Company's Cotton Valley Sand liquids rich natural gas properties located in East Texas. The Company currently expects that sales of these properties would occur during the third quarter of 2012.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) stock increased 31.58% to $1.75 in the early hour after the company announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus. Final data from the PEARL-SC clinical study with 200mg weekly blisibimod suggest sustained and greater treatment effects versus placebo utilizing 6, 7, and 8-point improvements in the SELENA-SLEDAI disease-scoring index.